Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

News [5784]

ASCO GU 2026: Combo targeting blood vessel growth controls ccRCC better than single agent

ASCO GU 2026: Combo targeting blood vessel growth controls ccRCC better than single agent

FDA grants accelerated approval to zongertinib for unresectable or metastatic non-squamous non-small cell lung cancer

FDA grants accelerated approval to zongertinib for unresectable or metastatic non-squamous non-small cell lung...

ASCO GU 2026: Enfortumab vedotin pembrolizumab combo may reduce risk of recurrence for some MIBC cases

ASCO GU 2026: Enfortumab vedotin pembrolizumab combo may reduce risk of recurrence for some MIBC cases

FDA approves acalabrutinib with venetoclax for chronic lymphocytic leukeamia or small lymphocytic lymphoma

FDA approves acalabrutinib with venetoclax for chronic lymphocytic leukeamia or small lymphocytic lymphoma

Senescence behind the aggressive nature of postpartum breast cancer

Senescence behind the aggressive nature of postpartum breast cancer

Existing drug unlocks immunotherapy potential against rare liver cancer

Existing drug unlocks immunotherapy potential against rare liver cancer

Sensing local fibers in pancreatic tumours, cancer cells ‘choose’ to either grow or tolerate treatment

Sensing local fibers in pancreatic tumours, cancer cells ‘choose’ to either grow or tolerate treatment

Telehealth improves access to genetic services for adult survivors of childhood cancers

Telehealth improves access to genetic services for adult survivors of childhood cancers

Lung cancer drug offers a surprising new treatment against ovarian cancer

Lung cancer drug offers a surprising new treatment against ovarian cancer

Call for action on understudied lung cancer in never-smokers

Call for action on understudied lung cancer in never-smokers

More from ecancer